News | Defibrillator Monitors | April 05, 2019

HeartHero Personal Automated External Defibrillator Wins ACC.19 Innovation Challenge

“Elliot” unit designed to improve consumer access to lifesaving technology for sudden cardiac arrest victims

HeartHero Personal Automated External Defibrillator Wins ACC.19 Innovation Challenge

April 5, 2019 — Medical device startup HeartHero was the winner in the Innovation Challenge at the 2019 American College of Cardiology (ACC) conference, March 16-18 in New Orleans, for its ultraportable, affordable and user-friendly automated external defibrillator (AED).

Co-hosted with AngelMD, the ACC.19 Innovation Challenge provided a platform for a select group of entrepreneurs to pitch their ideas for innovative products to advance the field of cardiology. HeartHero, which was created with the mission to save more lives from sudden cardiac arrest (SCA), has developed a personal AED device to make lifesaving technology available to the consumer market. “Elliot,” the purse-sized device, weighs just over 1 pound, operates using store-bought batteries, includes step-by-step instructions and visual prompts, and features artificial intelligence and a partner smartphone app.

“HeartHero winning this event is nothing short of a tremendous accomplishment,” stated John Rumsfeld, M.D., Ph.D., chief innovation officer at the American College of Cardiology. “It shows that HeartHero addresses a critical health problem, and is doing so with a truly novel medical device.”

“We were impressed by HeartHero’s innovative spirit in identifying and tackling an important public health issue,” continued Ori Ben-Yehuda, M.D., ACC.19 Innovation Challenge judge. “Coupled with public education their highly portable defibrillator has the potential to save lives.”

Watch the VIDEO: Tricuspid Device Clinical Trial Overview, an interview with Ben-Yehuda at the 2018 Transcatheter Valve Therapies (TVT) annual meeting.

According to the Sudden Cardiac Arrest Foundation, SCA is one of the leading causes of death in the U.S. The majority of deaths from SCA occur because individuals are not administered a life-saving AED from emergency medical services (EMS) within the critical 7-minute time window. By creating an AED that is accessible to the consumer market, HeartHero will effectively enhance the chance of survival for individuals who experience SCA by enabling bystanders to administer lifesaving care, according to the company.

For more information: www.hearthero.com

Related Content

American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Overlay Init